Cited by 112Neuroinflammation and Neurodegeneration MechanismsTraumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury Research

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

The immunology of traumatic brain injury: a prime target for Alzheimer’s disease prevention

Open access

Abstract

A global health problem, traumatic brain injury (TBI) is especially prevalent in the current era of ongoing world military conflicts. Its pathological hallmark is one or more primary injury foci, followed by a spread to initially normal brain areas via cascades of inflammatory cytokines and chemokines resulting in an amplification of the original tissue injury by microglia and other central nervous system immune cells. In some cases this may predispose individuals to later development of Alzheimer's disease (AD). The inflammatory-based progression of TBI has been shown to be active in humans for up to 17 years post TBI. Unfortunately, all neuroprotective drug trials have failed, and specific treatments remain less than efficacious. These poor results might be explained by too much of a scientific focus on neurons without addressing the functions of microglia in the brain, which are at the center of proinflammatory cytokine generation. To address this issue, we provide a survey of the TBI-related brain immunological mechanisms that may promote progression to AD. We discuss these immune and microglia-based inflammatory mechanisms involved in the progression of post-trauma brain damage to AD. Flavonoid-based strategies to oppose the antigen-presenting cell-like inflammatory phenotype of microglia will also be reviewed. The goal is to provide a rationale for investigations of inflammatory response following TBI which may represent a pathological link to AD. In the end, a better understanding of neuroinflammation could open therapeutic avenues for abrogation of secondary cell death and behavioral symptoms that may mediate the progression of TBI to later AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1742-2094-9-185

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 98 references

Research works printed but not linked: 3

  1. Halama P: Ginkgo biloba: effectiveness of a special extract in patients with cerebral insufficiency. Munch Med Wochenschr 1991, 133:190–194.
  2. Arrigo CS, Weitbrecht WV: Clinical and Psychometric Evaluation of Ginkgo Biloba Extract in Chronic Cerebrovascular Diseases. John Libbey & Company, London; 1985.
  3. Lovell MK FM: Neuropsychiatry of Traumatic Brain Injury. Neuropsychological assessment. American Psychiatric Press, Washington, DC; 1994:152–153.

Cited by

Sorted by citations

Items 101–112 of 112

Metadata

Authors
Giunta, B., Obregon, D., Velisetty, R., Sanberg, P. R., Borlongan, C. V., & Tan, J.
Affiliations
  • James A. Haley Veterans' Hospital (US)
  • University of South Florida (US)
Corresponding author
Giunta, Brian
Venue
Journal of Neuroinflammation
Published
2012-08-01
Volume
9
Issue
1
Pages
185-185
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2097143517
Cited by
112
References
98
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 8 · 2022: 8 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 7 · 2017: 11 · 2016: 11 · 2015: 14 · 2014: 10 · 2013: 7 · 2012: 2
FWCI
0.98
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Institute of Mental Health (R01MH098737)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
Keywords
traumatic brain injury, Alzheimer's disease, neuroinflammation, microglia, inflammatory cytokines, chemokines, secondary injury, flavonoids, neuroprotection, armed conflict
MeSH terms
Alzheimer Disease, Animals, Brain, Brain Injuries, Humans, Disease Progression, Inflammation Mediators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review